je.st
news
Tag: investigational
Mercks Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma
2014-06-30 12:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the companys investigational anti-PD-1 antibody, for the treatment of advanced melanoma. If approved by the European Commission (EC), pembrolizumab has the potential to be the first anti-PD-1 therapy in Europe. Language: English Contact: Media:Steve Cragle, 973-432-4781Claire Mulhear, 908-423-7425orInvestors:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
europe
treatment
Merck to Present New Clinical Data on JANUVIA (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association
2014-06-06 14:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will present 13 new studies and analyses, including data for its DPP-4 inhibitor JANUVIA (sitagliptin) and for its investigational once-weekly DPP-4 inhibitor omarigliptin, at the 74th Scientific Sessions of the American Diabetes Association (ADA) being held in San Francisco, June 13-17, 2014. Several analyses of patient data in real-world settings will also be presented. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orKim Hamilton908-423-6831 or 908-391-0131orInvestor:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Data on Mercks Pembrolizumab from Largest Study to Date of Investigational Anti-PD-1 Antibody in Advanced Melanoma Highlighted at ASCO 2014
2014-06-02 13:30:00| Merck.com - Corporate News
Dateline City: CHICAGO Pembrolizumab as Monotherapy Shows Estimated Overall Survival Rate of 69 Percent at One Year Across 411 Advanced Melanoma Patients with Varying Stages of Disease and Prior Therapy Durable Responses and Consistent Tolerability Profile Observed Across Doses, Including Patients With or Without Prior Ipilimumab Therapy Phase 3 Trials Ongoing or Planned Across Lines of Therapy, Including Adjuvant Treatment CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data from the companys large ongoing Phase 1b study (KEYNOTE-001) evaluating pembrolizumab (MK-3475), Mercks investigational anti-PD-1 antibody, as a single agent (monotherapy) in 411 patients with advanced melanoma. Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: date
data
advanced
study
First Presentation of Data for Pembrolizumab, Mercks Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014
2014-06-02 13:30:00| Merck.com - Corporate News
Dateline City: CHICAGO Initial Therapy with Pembrolizumab Demonstrates Robust Anti-Tumor Activity with Tumor Shrinkage in 80 Percent of Evaluable PD-L1 Positive, Advanced NSCLC Patients Merck Initiating Phase 3 Study with Pembrolizumab Versus Platinum-Based Doublet Chemotherapy as First-Line Therapy in PD-L1 Positive, Advanced NSCLC (KEYNOTE-024) Additional 50 Patients Enrolled in KEYNOTE-001 with Analyses Planned Using Mercks Proprietary PD-L1 Assay at One Percent and 50 Percent Cut Points CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data evaluating pembrolizumab (MK-3475), Mercks investigational anti-PD-1 antibody, as initial therapy in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC). Language: English Contact: MerckMedia Contacts:Ian McConnell, (973) 901-5722orClaire Mulhearn, (908) 423-7425orInvestor Contacts:Carol Ferguson, (908) 423-4465orJustin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
cell
presentation
First Presentation of Early Data for Pembrolizumab (MK-3475), Mercks Investigational Anti-PD-1 Antibody, in Advanced Head and Neck Cancer at ASCO 2014
2014-06-01 15:23:00| Merck.com - Corporate News
Dateline City: CHICAGO Overall Response Rate of 20 Percent for Pembrolizumab as Single Agent in Patients with Advanced Head and Neck Cancer Merck Initiating Phase 3 Study in Advanced Head and Neck Cancer with Pembrolizumab Versus Standard of Care in Q3 2014 (KEYNOTE-040) Additional 110 Patients with Advanced Head and Neck Cancer to be Enrolled in KEYNOTE-012 with Assessment of PD-L1 Tumor Levels Planned Pembrolizumab Announced as New Generic Name for MK-3475 CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of early findings from a Phase 1b study (KEYNOTE-012) evaluating pembrolizumab (MK-3475), Mercks investigational anti-PD-1 antibody, as a single-agent (monotherapy) in patients with PD-L1 positive, advanced head and neck cancer. Language: English Contact: MerckMedia Contacts:Ian McConnell, (973) 901-5722orClaire Mulhearn, (908) 423-7425orInvestor Contacts:Carol Ferguson, (908) 423-4465orJustin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
head
early
Sites : [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] next »